Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK2 | Q16620 | 3/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | RAF1 | P04049 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 6/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091887 | 1.00 | NTRK2 (0.69) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL398006 | 0.96 | NTRK2 (0.67) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL10091869 | 0.96 | NTRK2 (0.67) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL395674 | 0.95 | CSF1R (0.65) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL10091867 | 0.95 | CSF1R (0.65) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL396894 | 0.91 | NTRK2 (0.69) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL10091918 | 0.91 | NTRK2 (0.69) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL396191 | 0.91 | NTRK2 (0.65) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL10091881 | 0.91 | NTRK2 (0.65) | NTRK2NTRK1AURKARAF1SRC | |
| SCHEMBL394405 | 0.91 | CSF1R (0.64) | NTRK2NTRK1AURKARAF1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |